Atorvastatin Calcium
Product Images NDC 43353-115

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 43353-115). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 10mg (43353 0115 45)

Bottle Label 10mg (43353 0115 45)
Atorvastatin Calcium is a medication presented in the form of 45 tablets of 10mg each. It is labeled with an NDC number of 43353-0115-45 and instructions to store between 20-25 degrees Celsius. It appears to be repackaged by Aphena Pharma in Cockeville, TN with a reference to Toronto, Canada.*
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Chemical Structure- Atorvastatin Calcium (Image 01)

Chemical Structure- Atorvastatin Calcium (Image 01)
FDA Label Image

Figure 1 (Image 02)

Figure 1 (Image 02)
FDA Label Image

Figure 2 (Image 03)

Figure 2 (Image 03)
The text represents a cumulative hazard curve showing the percentage of participants experiencing the primary endpoint over 4 years of follow-up. The curve compares the placebo group to the group treated with Atorvastatin. The hazard ratio (HR) between the two groups is 0.63 with a confidence interval from 0.48 to 0.83 (p=0.001). The x-axis of the graph shows the time to the first primary endpoint (in years).*
FDA Label Image

Figure 3 (Image 04)

Figure 3 (Image 04)
This text shows data from a study comparing the effectiveness of two different doses of Atorvastatin in reducing the occurrence of major cardiovascular events over four years. The percentage of subjects who experienced such an event is not stated clearly, but it appears to be very low based on the numbers given. The higher dose of Atorvastatin was associated with a significantly lower risk of experiencing a cardiovascular event (HR 0.78, p=0.0002). The graph shows the time to the first major cardiovascular event over four years.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.